导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -15.69% | 4142/4773 |
| 近一周 | -2.92% | 4403/5465 |
| 近一月 | -0.36% | 791/5421 |
| 近一季 | -1.43% | 1210/5231 |
| 近半年 | -6.46% | 3204/4920 |
| 近一年 | -11.05% | 3475/4394 |
| 近两年 | 32.80% | 2176/2954 |
| 近三年 | 17.17% | 1576/2253 |
| 成立以来 | 150.80% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-16.29% 4744/4961 |
1.23% 3059/5312 |
- - |
- - |
| 2025 | 13.72% 2631/4813 |
-6.00% 3334/3635 |
7.22% 398/4076 |
6.45% 3524/4524 |
5.99% 385/4813 |
| 2024 | 36.49% 49/3463 |
-2.87% 1448/2808 |
-3.34% 1352/3014 |
43.47% 9/3129 |
1.34% 1083/3463 |
| 2023 | -2.68% 598/2656 |
1.19% 1620/2280 |
0.19% 335/2385 |
5.81% 82/2515 |
-9.29% 2333/2655 |
| 2022 | -17.98% 647/2207 |
-15.60% 1051/1919 |
2.94% 1237/2016 |
-14.58% 1118/2113 |
10.52% 170/2208 |
| 2021 | -15.02% 1153/1822 |
-11.65% 1139/1255 |
-2.16% 1193/1330 |
-4.19% 686/1466 |
2.60% 557/1822 |
| 2020 | 12.75% 809/1250 |
-15.42% 980/1028 |
9.29% 798/1067 |
16.05% 175/1164 |
5.10% 805/1184 |
| 2019 | 47.99% 116/1092 |
40.74% 50/754 |
3.60% 46/804 |
-3.20% 732/850 |
4.85% 773/918 |
| 2018 | -23.11% 269/834 |
- - |
- - |
- - |
-11.18% 257/691 |
| 2017 | 22.02% 155/714 |
- - |
- - |
- - |
- - |
| 2016 | -10.60% 283/605 |
- - |
- - |
- - |
- - |
| 2015 | -20.70% 301/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达沪深300非银ETF VS. 长安沪深300非周期A(740101) |